Lora-Mepha Allergie (Loratadine) is used to manage key allergic manifestations and provide symptomatic support. It is indicated for the symptomatic management of symptoms related to inflammatory or irritative states. The medication is commonly used across conditions characterized by periods of heightened symptoms, such as seasonal hay fever and perennial allergic rhinitis, and is relevant for easing the discomfort associated with hives (urticaria) and generalized pruritus (itching).

---

Relief for Hay Fever and Nasal Allergy Symptoms

Lora-Mepha Allergie is applied in scenarios where additional management of discomfort is appropriate for symptoms related to inflammatory or irritative states, such as persistent sneezing, disruptive runny nose (rhinorrhea), and localized itching of the nose and throat. It provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability and comfort during periods of heightened allergen exposure.

“It is relevant for managing symptoms that interfere with daily comfort, especially when multiple symptoms occur together.”

The long-acting action of this medication supports the patient during difficult episodes by easing distress. The non-sedating profile assists with maintaining functional stability, contributing to ease during symptomatic periods across nasal, ocular, and cutaneous domains.

---

Quick Fact: Relief for Allergic Symptoms

Symptom Domain	Conditions Managed	Key Benefit
Upper Respiratory	Seasonal/Perennial Allergic Rhinitis, Hay Fever	Eases sneezing and runny nose.
Cutaneous	Urticaria (Hives), Allergic Pruritus	Supports relief from intense itching.
Ocular	Allergic Conjunctivitis	Helps with itchy, watery eyes.

Regulatory References

1. NIH MedlinePlus overview of Loratadine

Official Eligibility and Contraindications

The eligibility for Lora-Mepha Allergie (Loratadine 10 mg tablet) is defined by official regulatory documents across age, existing conditions, and physiological states.

Populations Contraindicated

Classification	Prohibition Statement
Hypersensitivity	Contraindicated in individuals with known hypersensitivity to Loratadine or any excipients.
Metabolic Disorders	Contraindicated for patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to lactose content).

Age-related Eligibility and Restrictions

• Adults and Adolescents (over 12 years of age): Permitted for standard use.
• Children 6 to 12 years: The 10 mg tablet is typically restricted to children with a body weight greater than 30 kg.
• Children under 6 years or < 30 kg: The 10 mg tablet is not appropriate (formulation restriction).
• Children under 2 years: Safety and efficacy has not been established.
• Elderly Patients: No dosage adjustments are required.

Condition-Specific and Conditional Use

• Severe Liver Impairment: Use requires caution; a lower initial dose of 10 mg every other day is recommended.
• Renal Impairment: No dosage adjustments are required.

Pregnancy and Lactation Status

Use is not recommended during pregnancy (as a precautionary measure) and is not recommended during breastfeeding because Loratadine is excreted in breast milk.

Lora-Mepha Allergie (loratadine) may interact with certain other medicines that are processed in the liver. These interactions primarily involve the Cytochrome P450 (CYP) enzyme systems, specifically CYP3A4 and CYP2D6, which are responsible for metabolizing loratadine.

Documented Pharmacokinetic Interactions

• Enzyme Inhibitors: Co-administration with known inhibitors of these enzymes may increase the plasma concentration of loratadine. Medicines for which this effect has been specifically documented in clinical studies include Ketoconazole (an antifungal), Erythromycin (an antibiotic), and Cimetidine (an acid reducer).
• General Precaution: It is advised to use caution when taking this medicine with any other product that is primarily metabolized by the liver, particularly those involving the CYP3A4 and CYP2D6 isoenzymes.

Interactions with CNS Depressants

• Alcohol: Official studies indicate that this medicine does not potentiate the sedative or performance-impairing effects of alcohol.
• Diazepam: No clinically significant interactions have been observed with the concurrent use of Diazepam.

Clinical Relevance

While co-administration with enzyme inhibitors can lead to higher loratadine levels, clinical studies often show no associated increase in common side effects, such as changes in vital signs or EKG results. However, patients should still inform a healthcare professional of all current medications, including over-the-counter and herbal supplements, before starting treatment.

The mechanism of Lora-Mepha Allergie centers on its primary active molecule, desloratadine, which is metabolized from the parent compound, loratadine. This molecule functions as a Competitive Antagonist at the peripheral Histamine mathbfH1-receptors. This crucial interaction prevents the binding of the endogenous mediator, histamine, thereby interrupting the signaling cascade initiated by the allergic response.

The mechanism exhibits Peripheral Selectivity due to the molecule's restricted ability to penetrate the Blood-Brain Barrier. This selectivity ensures that antagonism is confined primarily to receptors outside the Central Nervous System. The mathbfH1-receptor blockade immediately initiates a cascade that interrupts histamine-driven increases in vascular permeability and sensory nerve excitation. The resulting physiological consequence is decreased histamine-induced microvascular extravasation and inhibition of sensory nerve excitation. Furthermore, the long plasma half-life of desloratadine maintains continuous, high-affinity receptor occupancy, contributing to sustained modulation of the acute inflammatory response.

How to Use Lora-Mepha Allergie: Administration Guidelines

Lora-Mepha Allergie (Loratadine) is intended for oral administration and is typically taken once daily, reflecting its long duration of action. Standard administration parameters define the dose and required adjustments.

---

Administration Scope

Feature	Instruction
Dosing schedule (Adults and children 6 years and older):	10 mg once daily (maximum 10 mg per 24 hours)
Dosing schedule (Children 2 to 5 years):	5 mg once daily (maximum 5 mg per 24 hours)
Timing in relation to meals:	Taken without regard to mealtime (with or without food)

---

Population-Specific and Special Administration Rules

A modification of the dosing interval is utilized for patients with significant impairment. For individuals 6 years and older with severe hepatic impairment or severe renal impairment (glomerular filtration rate < 30 mL/min), the initial dose is typically 10 mg every other day. A corresponding dose reduction to 5 mg every other day applies to children 2 to 5 years with these severe impairments.

A key procedural restriction requires the medicine to be discontinued for at least 48 hours prior to any planned allergy skin testing to prevent interference with test results.

---

Resulting Procedural Structure

Step sequence:

• Determine the appropriate daily dose based on age/weight classification and the patient's clearance status.
• Swallow the determined dose of the tablet once every 24 hours.
• Consume the dose irrespective of the timing of food intake.
• Cease administration 48 hours before allergy skin testing.

Connection to the overall use protocol: The administration guidelines establish a fixed procedural structure defining the oral route, a fixed once-daily frequency, and the maximum allowed dose based on the patient's age and clinical clearance status. This framework details specific dose adjustments and a required temporary cessation rule before specific medical procedures, ensuring consistent administration.

Recent Clinical Evidence

Clinical trials involving loratadine (the active ingredient in Lora-Mepha Allergie) have primarily investigated its profile in treating symptoms associated with seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives).

Efficacy Studies

Randomized controlled trials (RCTs) have compared loratadine against placebo and other antihistamines in adults and adolescents.

• Allergic Rhinitis: Studies indicate that loratadine is associated with relief of key nasal and non-nasal symptoms, including sneezing, runny nose, and itchy eyes. One post-hoc analysis suggested an onset of action for symptom relief as early as 75 minutes in adults with seasonal allergic rhinitis, compared to placebo.
• Urticaria: For chronic hives, loratadine has been studied for its ability to reduce associated pruritus (itching) and erythema (redness). Research supports its use in managing these symptoms compared to placebo.

Safety and Tolerability

Loratadine belongs to the second-generation antihistamine class, which is noted in clinical literature for having a favorable safety profile compared to first-generation options.

Common Adverse Events (Reported in Trials)
Mild Dizziness
Headache
Somnolence (Drowsiness)
Fatigue
Dry Mouth

In multiple large trials involving the recommended dosage, the incidence of reported somnolence (drowsiness) was found to be similar to that of placebo. Loratadine is also studied in combination with other agents, such as nasal corticosteroids and decongestants, with research assessing the overall patient response and safety profile of the combination regimens.

Key Studies & References

1. Loratadine - StatPearls - NCBI Bookshelf (for general safety and adverse effects profile)
2. Label: LORATADINE tablet - DailyMed - NIH (for regulatory indication and dosage information)
3. Appropriate use of second-generation antihistamines - Cleveland Clinic Journal of Medicine (for context on second-generation safety/sedation)

Common questions about Lora-Mepha Allergie (FAQ)

Q: How quickly should I expect Lora-Mepha Allergie to start working?

Clinical studies investigating the active ingredient indicate that relief from allergy symptoms, such as those caused by seasonal allergic rhinitis, has been reported to occur as early as 75 minutes after administration. This information is based on controlled research evidence.

Q: What happens if I miss taking a dose of Lora-Mepha Allergie?

If a dose is missed, official drug guidance generally recommends taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should generally be skipped, and the user should resume their regular schedule. This practice helps prevent taking more than the allowed maximum dose within a 24-hour period.

Q: Is it possible for Lora-Mepha Allergie to cause a dry mouth?

Yes, regulatory documents list dry mouth as a common side effect associated with the use of the medicine’s active ingredient. The occurrence of dry mouth is consistent with the known effects listed in post-marketing safety data.

Q: Are there any specific foods or drinks to avoid while taking Lora-Mepha Allergie?

According to official product information, the medicine can be taken with or without food and studies show it does not increase the sedative effects of alcohol. Regulatory summaries advise caution regarding certain substances, such as grapefruit juice, that can affect the liver enzymes that process the medicine (CYP3A4), as this may alter its concentration in the body.

Q: Is Lora-Mepha Allergie the same as other well-known allergy medicines?

Lora-Mepha Allergie is formally classified as a second-generation H1-antihistamine. This classification is characterized by its restricted ability to affect the central nervous system, which is associated with a reduced potential for causing drowsiness compared to older medications.

Q: Can Lora-Mepha Allergie be taken with pain relievers like ibuprofen?

Regulatory interaction databases and professional guidance indicate that there are typically no known or documented interactions between the medicine's active ingredient and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Information regarding co-administered medications should be shared with a healthcare professional.

Q: Are there any known issues with taking Lora-Mepha Allergie alongside certain supplements?

The active ingredient is processed by specific liver enzymes. Official warnings advise caution for any supplement known to inhibit these enzymes (CYP3A4 and CYP2D6), as this interaction could potentially alter the concentration of the medicine in the body. Disclosure of all supplements and herbals to a healthcare professional is consistent with standard safety practice.

Q: How long does the effect of Lora-Mepha Allergie usually last?

The medicine is generally used for once-daily administration because the active ingredient has a long duration of action. Based on official dosing guidelines, the intended therapeutic effect is designed to last for approximately 24 hours.

Q: Is Lora-Mepha Allergie suitable for treating pet allergy symptoms?

Yes, official regulatory indications state the active ingredient is used for the relief of symptoms associated with allergic rhinitis, which includes symptoms triggered by animal dander. The medicine works by mitigating the general physical manifestations of an allergic response, regardless of the specific trigger.

Q: Is Lora-Mepha Allergie available in a generic version?

Yes, the active ingredient in Lora-Mepha Allergie, loratadine, is now widely available from multiple manufacturers under its generic name. This is reflected in official government drug listings and formularies.

Q: Is there a difference in strength between the tablets and liquid forms of Lora-Mepha Allergie?

According to official dosing charts, the standard adult dose for the tablet form (10 mg) is equivalent to the standard dose for the liquid or syrup dosage forms (e.g., 10 mg of liquid). The total amount of active ingredient per dose is described as the same.

Q: Can Lora-Mepha Allergie cause problems with sleep?

While the medicine is generally non-sedating, official documents list both somnolence (drowsiness) and, in some rare cases, insomnia (difficulty sleeping) as possible side effects. As with any medication, individual responses should be monitored.

Q: Is there research on the use of Lora-Mepha Allergie for food allergy reactions?

Official clinical indications and research documentation primarily focus on the use of the active ingredient for the treatment of symptoms related to seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). Treatment for food allergy reactions is not typically listed as an official or standard approved use.

Q: What if I take Lora-Mepha Allergie and my symptoms do not improve?

Consumer information found in official sources advises that if allergy symptoms persist, worsen, or are not relieved despite using the medicine, a healthcare professional should be contacted. This allows for professional review of the continued management of symptoms.

Q: Can Lora-Mepha Allergie be taken if I am planning to drive?

Official documents state that effects on the ability to drive or operate machinery have not been observed in clinical trials. However, due to the rare possibility of side effects like drowsiness, caution is advised, and users are generally encouraged to monitor their individual response before driving.

Q: Are there official warnings about taking Lora-Mepha Allergie with specific antidepressants?

Official warnings focus broadly on drugs that inhibit the CYP3A4 and CYP2D6 liver enzymes, which process the medicine. Because some antidepressants fall into these categories, regulatory texts advise healthcare professionals to use caution when co-administering any such products that may affect drug levels.

Q: Can I use Lora-Mepha Allergie if I am scheduled for surgery soon?

Official clinical guidance typically suggests that the medicine may be continued for elective and emergency surgery. Official guidance indicates that healthcare professionals, including the surgical team, should be informed of all current medications before any procedure.

Q: Does Lora-Mepha Allergie have known interactions with proton pump inhibitors (PPIs)?

Regulatory interaction screening for the active ingredient and common proton pump inhibitors (PPIs) generally shows no known interaction. Caution with all co-administered medications is routinely cited in regulatory summaries.

Q: What official information is available regarding Lora-Mepha Allergie and heart rhythm conditions?

Official safety documents note that post-marketing surveillance has very rarely reported events such as abnormally fast heart rate (tachycardia) and heart palpitations. This information is provided in regulatory documentation for healthcare professionals, especially when managing individuals with existing heart rhythm conditions.

How to Store and Dispose of Lora-Mepha Allergie

For proper storage and disposal of Lora-Mepha Allergie (loratadine) tablets, official regulations must be followed to maintain drug stability and protect the environment.

Storage Requirement	Official Statement
Temperature	Do not store above 25°C (or 30°C as specified on the label). Do not freeze.
Protection	Keep the tablets in the original packaging and ensure the container is tightly closed to protect from moisture and light.
Stability	Do not use this medicine after the expiry date (EXP) printed on the carton.
Children's Access	Keep all medicines out of the sight and reach of children.

Disposal:

To prevent environmental contamination, do not dispose of Lora-Mepha Allergie in household waste or wastewater. Expired or unused medicines must be returned to a pharmacy or designated collection point. This is the official method for safely disposing of the product.